DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

计划入组 900 人 · 首次发布于 2024 年 4 月 29 日

An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

首次发布于 2025 年 4 月 23 日

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

计划入组 344 人 · 首次发布于 2025 年 11 月 18 日

anti-inflammatory agent (rheumatoid arthritis associated interstitial lung disease)

Pulmonary Hypertension(Vascugen)

NOTCH inhibitors (pulmonary hypertension)

Avantis Emerging Markets Equity Active ETF

United States

HARVEST TRAVEL & LEISURE INCOME ETF UNIT CL A

United States

Pulmonary Associates Of Richmond, Inc.

United States

Pulmovant Completes Enrollment in Phase 2 Trial of Mosliciguat for Pulmonary Hypertension Associated with Interstitial Lung Disease

Liquidia's Yutrepia Receives Tentative FDA Approval for Pulmonary Hypertension

Foresee Pharmaceuticals Launches Phase 2 Trial of Mirivadelgat for Pulmonary Hypertension Associated with Interstitial Lung Disease